Latest Breaking News On - Vince anzalone - Page 4 : comparemela.com

Arrowhead Pharmaceuticals, Inc (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript August 7, 2023 Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions. I will now hand the conference over to Vince Anzalone, […]

United statesChris anzaloneKen myszkowskiJames hamiltonEuropean respiratory society international congressEuropean atherosclerosis society congressMyriam zillesAmerican heart associationHomozygous familial hypercholesterolemiaHeterozygous familial hypercholesterolemiaMixed dyslipidemiaRoyalty pharmaPaying programming languagesGold mining stocks to buyVince anzaloneJames hamilton

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 f

PASADENA, Calif. (BUSINESS WIRE) $arwr Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for pa.

New zealandBrian ritchieVince anzaloneChris anzaloneJason bracoStanding committee on therapeutic trialsExchange commissionLifesci communicationsDevices safety authorityLifesci advisorsArrowhead pharmaceuticals incArrowhead pharmaceuticalsNew zealand medicinesMedical devices safety authorityStanding committeeHarbor statement

Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1

Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jason bracoBrian ritchieVince anzaloneChris anzaloneLifesci advisorsArrowhead pharmaceuticalsLifesci communicationsTherapeutic goods administrationExchange commissionArrowhead pharmaceuticals incAustralian department of healthClinical trial notificationAustralian departmentTherapeutic goodsHarbor statementPrivate securities litigation reform act

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris anzaloneBrian ritchieJason bracoVince anzaloneTherapeutic goods administrationExchange commissionAustralian department of healthArrowhead pharmaceuticalsLifesci communicationsLifesci advisorsArrowhead pharmaceuticals incClinical trial notificationAustralian departmentTherapeutic goodsHarbor statementPrivate securities litigation reform act

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesVince anzaloneJason bracoBrian ritchieArrowhead pharmaceuticalsLifesci communicationsArrowhead pharmaceuticals incDrug administrationLifesci advisorsExchange commissionPresented during oral sessionPromising impactKey markersLiver diseaseRare genetic disease affecting childrenApproved treatments